Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | JAK1 | P23458 | 3/20 | 0.40 |
| ▸ | TYK2 | P29597 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849475 | 1.00 | USP30 (0.42) | USP30PARP1GPR119L3MBTL1JAK2 | |
| SCHEMBL2854036 | 0.86 | JAK3 (0.40) | JAK3 | |
| SCHEMBL2854038 | 0.86 | JAK3 (0.40) | JAK3 | |
| SCHEMBL2852662 | 0.85 | L3MBTL1 (0.47) | USP30PARP1GPR119L3MBTL1JAK2 | |
| SCHEMBL2852657 | 0.85 | L3MBTL1 (0.47) | USP30PARP1GPR119L3MBTL1JAK2 | |
| SCHEMBL2844369 | 0.81 | USP30 (0.42) | USP30PARP1GPR119L3MBTL1BTK | |
| SCHEMBL2847457 | 0.81 | HDAC4 (0.42) | USP30PARP1GPR119L3MBTL1JAK3 | |
| SCHEMBL2844364 | 0.81 | USP30 (0.42) | USP30PARP1GPR119L3MBTL1BTK | |
| SCHEMBL2847459 | 0.81 | HDAC4 (0.42) | USP30PARP1GPR119L3MBTL1JAK3 | |
| SCHEMBL2848258 | 0.79 | PARP1 (0.45) | USP30PARP1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2226322-B1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8927588-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8536197-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-17 | — | — | US | disclosed |
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226322-A1 | IMIDAZOLE CARBONYL COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | USP30 2702/4885PARP1 21/4885GPR119 4537/4885 |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | USP30 3354/4885PARP1 10/4885GPR119 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.